Richard Wiegand
About
In The Last Decade
Richard Wiegand
23 papers receiving 389 citations
Peers
Comparison fields: 5 of 90
- Molecular Biology 172
- Oncology 145
- Pathology and Forensic Medicine 45
- Organic Chemistry 45
- Pharmacology 39
Countries citing papers authored by Richard Wiegand
This map shows the geographic impact of Richard Wiegand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Wiegand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Wiegand more than expected).
Fields of papers citing papers by Richard Wiegand
This network shows the impact of papers produced by Richard Wiegand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Wiegand. The network helps show where Richard Wiegand may publish in the future.
Co-authorship network of co-authors of Richard Wiegand
This figure shows the co-authorship network connecting the top 25 collaborators of Richard Wiegand. A scholar is included among the top collaborators of Richard Wiegand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Wiegand. Richard Wiegand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 32 | |
| 2 | 1 | |
| 3 | 30 | |
| 4 | 33 | |
| 5 | 1 | |
| 6 | 5 | |
| 7 | 21 | |
| 8 | 10 | |
| 9 | 56 | |
| 10 | 23 | |
| 11 | 59 | |
| 12 | 12 | |
| 13 | 6 | |
| 14 | 15 | |
| 15 | 3 | |
| 16 | 13 | |
| 17 | 4 | |
| 18 | Preclinical anticancer activity of cryptophycin-8. | 25 |
| 19 | Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. | 7 |
| 20 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.